Biomex

Biomex

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $9.8M

Overview

BIOMEX is a well-established, private German company that has positioned itself as a critical infrastructure provider in the life sciences and diagnostics sectors. Its core business revolves around a massive biobank and sample procurement network, supplying high-quality human raw materials (blood, tissue, cells) and supporting services from basic research through to IVD regulatory approval. The company leverages strategic donation centers in Germany and Cameroon, a vast partner network, and in-house laboratory capabilities to offer reliability, speed, and compliance, particularly under the stringent EU IVDR. Its model is built on enabling client R&D by removing bottlenecks in sample sourcing and testing.

DiagnosticsGenetics & GenomicsProteomics

Technology Platform

Integrated biospecimen ecosystem comprising a massive biobank (Sampleshop), a global procurement network (own donation centers & partner clinics), in-house processing/analytical laboratories, and a dedicated IVD CRO framework for regulatory performance evaluations.

Funding History

2
Total raised:$9.8M
Series A$8M
Seed$1.8M

Opportunities

The stringent EU IVDR creates a large, sustained demand for specialized CRO services for diagnostic performance evaluations, a niche BIOMEX exclusively serves.
The growth of personalized medicine and cell/gene therapies drives need for well-characterized human biospecimens and cellular starting materials, aligning with the company's core inventory and services.

Risk Factors

Operational risks include disruption of the complex, ethics-sensitive global supply chain for human biological materials.
The business is also exposed to regulatory changes in the IVD space and intense competition in the biospecimen market, which could pressure margins.

Competitive Landscape

BIOMEX competes in a fragmented global market for biospecimens and research services against large commercial biobanks (e.g., Discovery Life Sciences, BioIVT), diagnostic CROs, and academic tissue banks. Its key differentiators are the scale of its immediately available inventory in Europe, its integrated IVD CRO, and its strategic donor centers providing geographic diversity.